Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data.

Choong CK, Ford JH, Nyhuis AW, Joshi SG, Robinson RL, Aurora SK, Martinez JM.

Headache. 2017 Oct;57(9):1359-1374. doi: 10.1111/head.13127. Epub 2017 Jun 5.

2.

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.

Clemow DB, Nyhuis AW, Robinson RL.

CNS Neurosci Ther. 2016 Dec;22(12):970-978. doi: 10.1111/cns.12595. Epub 2016 Jul 31.

3.

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.

Ascher-Svanum H, Weiden P, Nyhuis AW, Faries DE, Stauffer V, Kollack-Walker S, Kinon BJ.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):84-90, 90A. doi: 10.3371/CSRP.ASWE.022213.

PMID:
23446198
4.

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.

Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ.

BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142.

5.

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians.

Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP.

Patient Prefer Adherence. 2011;5:547-54. doi: 10.2147/PPA.S23255. Epub 2011 Nov 3.

6.

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.

Ascher-Svanum H, Zhao F, Detke HC, Nyhuis AW, Lawson AH, Stauffer VL, Montgomery W, Witte MM, McDonnell DP.

BMC Psychiatry. 2011 Sep 23;11:152. doi: 10.1186/1471-244X-11-152.

7.

Predictors of switching antipsychotic medications in the treatment of schizophrenia.

Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ.

BMC Psychiatry. 2010 Sep 28;10:75. doi: 10.1186/1471-244X-10-75.

8.

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.

Ascher-Svanum H, Nyhuis AW, Stauffer V, Kinon BJ, Faries DE, Phillips GA, Schuh K, Awad AG, Keefe R, Naber D.

Curr Med Res Opin. 2010 Oct;26(10):2403-10. doi: 10.1185/03007995.2010.515900.

PMID:
20812791
9.

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Ball DE, Kinon BJ.

BMC Psychiatry. 2010 Jan 28;10:11. doi: 10.1186/1471-244X-10-11.

10.

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.

Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ.

BMC Psychiatry. 2009 Sep 2;9:54. doi: 10.1186/1471-244X-9-54.

11.

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.

Faries DE, Nyhuis AW, Ascher-Svanum H.

Cost Eff Resour Alloc. 2009 May 27;7:11. doi: 10.1186/1478-7547-7-11.

12.

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.

Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ.

Curr Med Res Opin. 2008 May;24(5):1399-405. doi: 10.1185/030079908X297385 . Epub 2008 Apr 7.

PMID:
18397549
13.

Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A.

Schizophr Bull. 2008 Nov;34(6):1163-71. Epub 2007 Dec 21.

14.

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.

Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum H.

J Clin Psychopharmacol. 2006 Dec;26(6):666-7. No abstract available.

PMID:
17110828
15.

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.

Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R.

Value Health. 2006 Mar-Apr;9(2):77-89.

16.

Outcomes of American Lung Association-Indiana Lung Centers asthma program.

Summers KH, Zillich AJ, Nyhuis AW, Twigg HL 3rd.

Dis Manag. 2005 Oct;8(5):311-8.

PMID:
16212516
17.

Alterations in predicted growth rates of pediatric kidneys treated with extracorporeal shockwave lithotripsy.

Lifshitz DA, Lingeman JE, Zafar FS, Hollensbe DW, Nyhuis AW, Evan AP.

J Endourol. 1998 Oct;12(5):469-75.

PMID:
9847072
18.

The use of a break-even analysis: financial analysis of a fast-track program.

Saywell RM Jr, Cordell WH, Nyhuis AW, Giles BK, Culler SD, Woods JR, Chu DK, McKinzie JP, Rodman GH Jr.

Acad Emerg Med. 1995 Aug;2(8):739-45.

19.

Community hospital and medical school cooperation in continuing medical education.

Jay SJ, Casebeer L, Woods JR, Nyhuis AW, O'Toole JB.

Acad Med. 1995 Feb;70(2):136-41.

PMID:
7865040
20.

Does anybody really know what time it is? Does anybody really care?

Cordell WH, Olinger ML, Kozak PA, Nyhuis AW.

Ann Emerg Med. 1994 May;23(5):1032-6.

PMID:
8185095

Supplemental Content

Loading ...
Support Center